

## REMARKS

The Examiner has required restriction under 35 U.S.C. § 121 to one of the following groups:


Group I. Claims 1-27 and 30-31 drawn to a method for treating an angiotensin II related disease in a patient, comprising administering to a patient in need thereof an effective amount of a compound of formula I or a 3-enol C<sub>1-4</sub> alkanolate ester thereof; and

Group II. Claim 28 drawn to a pharmaceutical composition comprising a compound of formula I or a 3-enol C<sub>1-4</sub> alkanolate ester thereof and one or more of an ACE inhibitor; an angiotensin II receptor blocker; an inhibitor or agent used for lowering aldosterone levels or blocking the effects of aldosterone; or a steroidogenesis inhibitor.

In response, Applicants elect Group I, Claims 1-27 and 30-31 drawn to a method for treating an angiotensin II related disease in a patient, comprising administering to a patient in need thereof an effective amount of a compound of formula I or a 3-enol C<sub>1-4</sub> alkanolate ester thereof.

The further election of a particular angiotensin II related disease to be treated in the method of Group I or, alternatively, the election of a particular angiotensin II related disease listed in claims 5, 6, 9, 10 or 11 is required. In response, Applicants elect without traverse cardiofibrosis (*see* claim 10). Claims 1-4, 7-27, 30 and 31 read on the elected species.

The further election of a particular compound of formula I or a particular 3-enol C<sub>1-4</sub> alkanolate ester or, alternatively, a particular compound of formula I listed in claim 3 is required. In response, Applicants elect without traverse trilostane (*see* claim 3). Trilostane has the following structure and chemical name:



(4 $\alpha$ ,5 $\alpha$ ,17 $\beta$ )-4,5-epoxy-3,17-dihydroxyandrost-2-ene-2-carbonitrile. Claims 1-28, 30 and 31 read on the elected species.

The further election of the presence or absence of additional components is required and, if the presence of additional components is elected, the election of the particular components is required. In response, Applicants elect without traverse the absence of additional components. Claims 1-21 read on the elected species.

Claims 1-4, 7-21 read on all three elected species.

It is estimated that no fee is due in connection with this response other than the fee due in connection with the extension of time. In the event that any additional fee is required, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

*Anthony M. Insogna, Reg. No. 35,203*

*By: Michael J. Bruner, Reg. No. 47,458*

Date April 27, 2009

By: Michael J. Bruner (Reg. No. 47,458)

**JONES DAY**

222 East 41st Street

New York, New York 10017

(404) 581-8614

For: Anthony M. Insogna (Reg. No. 35,203)

**JONES DAY**

12265 El Camino Real, Suite 200

San Diego, California 92130

(858) 314-1130